About DelMar Pharmaceuticals
DelMar Pharmaceuticals is a company based in Vancouver (Canada) founded in 2010. DelMar Pharmaceuticals has raised $7.9 million across 10 funding rounds from investors including National Research Council Canada. The company has 3 employees as of June 30, 2022. DelMar Pharmaceuticals has completed 1 acquisition, including Adgero Biopharma. DelMar Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
- Headquarter Vancouver, Canada
- Employees 3 as on 30 Jun, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Delmar Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.9 M (USD)
in 10 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
3
as on Jun 30, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of DelMar Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of DelMar Pharmaceuticals
DelMar Pharmaceuticals has successfully raised a total of $7.9M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DelMar Pharmaceuticals
DelMar Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Research Council Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific and technological research is conducted for Canada's benefit.
|
Locked | Locked | Locked |
Investor details for DelMar Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DelMar Pharmaceuticals
DelMar Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adgero Biopharma.
Investment portfolio details for DelMar Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Photodynamic therapy for cutaneous metastatic breast cancer is developed.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for DelMar Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - DelMar Pharmaceuticals
Detailed financials for DelMar Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Delmar Pharmaceuticals Comparisons
Peer comparison for DelMar Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DelMar Pharmaceuticals
DelMar Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of DelMar Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Delmar Pharmaceuticals
Complete news archive for DelMar Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 and raised its 1st funding round 3 years after it was founded.
DelMar Pharmaceuticals is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
DelMar Pharmaceuticals is a funded company, having raised a total of $7.9M across 10 funding rounds to date.
As of Jun 30, 2022, the latest employee count at DelMar Pharmaceuticals is 3.
DelMar Pharmaceuticals was founded in 2010 and is headquartered in Vancouver, Canada. Operations center on the development of small molecule chemotherapies within the biotechnology sector. The lead candidate, VAL-083, targets refractory glioblastoma multiforme, with additional exploration for front-line glioblastoma and solid tumors such as non-small cell lung cancer and ovarian cancer. Focus remains on orphan cancer indications.
DelMar Pharmaceuticals's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
DelMar Pharmaceuticals has made 1 acquisition, including Adgero Biopharma.
DelMar Pharmaceuticals has 1 investor. Key investors include National Research Council Canada.